Listed

Pediatrix Medical Group, Inc.: Form 10-Q for the period ended Jun 30, 2019

Filed with the SEC on Aug 1, 2019 and accepted by EDGAR at Aug 1, 2019, 16:30 ET.

Share

Management's discussion and analysis

As filed, 48,424 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following discussion highlights the principal factors that have affected our financial condition and results of operations, as well as our liquidity and capital resources, for the periods described. This discussion should be read in conjunction with the unaudited Condensed Consolidated Financial Statements and the notes thereto included in this Quarterly Report. In addition, reference is made to our audited consolidated financial statements and notes thereto and related Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, filed with the Securities and Exchange Commission on February 14, 2019 (the “2018 Form 10-K”). As used in this Quarterly Report, the terms “MEDNAX”, the “Company”, “we”, “us” and “our” refer to the parent company, MEDNAX, Inc., a Florida corporation, and the consolidated subsidiaries through which its businesses are actually conducted (collectively, “MDX”), together with MDX’s affiliated business corporations or professional associations, professional corporations, limited liability companies and partnerships (“affiliated professional contractors”). Certain subsidiaries of MDX have contracts with our affiliated professional contractors, which are separate legal entities that provide physician services in certain states and Puerto Rico. The following discussion contains forward-looking statements. Please see the Company’s 2018 Form 10-K, including Item 1A, Risk Factors, for a discussion of the uncertainties, risks and assumptions associated with these forward-looking statements. In addition, please see “Caution Concerning Forward-Looking Statements” below.

Overview

MEDNAX is a leading provider of physician services including newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology and other pediatric subspecialty care. Our national network is comprised of affiliated physicians who provide clinical care in 39 states and Puerto Rico. Our affiliated physicians provide neonatal clinical care, primarily within hospital-based neonatal intensive care units, to babies born prematurely or with medical complications; anesthesia care to patients in connection with surgical and other procedures, as well as pain management; radiology services including diagnostic imaging and interventional radiology; and maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where our affiliated neonatal physicians practice. Our network also includes other pediatric subspecialists, including those who provide pediatric intensive care, pediatric cardiology care, hospital-based pediatric care, pediatric surgical care, pediatric ear, nose and throat, pediatric ophthalmology and pediatric urology services. MEDNAX also provides teleradiology services in all 50 states, the District of Columbia and Puerto Rico through a network of affiliated radiologists. In addition to our national physician network, we provide services nationwide to healthcare facilities and physicians, including ours, through a consulting services company.

Divestiture of the Management Services Organization

On November 1, 2018, we announced the initiation of a process to potentially divest our management services service line to allow us to focus on our core physician services business. We determined that the criterion to classify the management services service line as assets and liabilities held for sale within our consolidated balance sheets were met at March 31, 2019 and continue to be met at June 30, 2019. Accordingly, the assets and liabilities of the management services service line were classified as current assets and liabilities held for sale as of March 31, 2019 and June 30, 2019. In addition, in accordance with the accounting guidance for discontinued operations, the expected divestiture of the management services service line was deemed to represent a fundamental strategic shift that will have a major effect on the Company’s operations, and accordingly, the operating results of the service line were reported as discontinued operations in the consolidated statements of income for the three and six months ended June 30, 2019.

Reclassifications

Reclassifications have been made to certain prior period financial statements and footnote disclosures to conform to the current period presentation, specifically to reflect the impact of the management services organization being classified as assets held for sale and discontinued operations.

2019 Acquisition Activity

During the six months ended June 30, 2019, we completed the acquisition of one neonatology physician group practice and two maternal-fetal medicine physician group practices. Based on our experience, we expect that we can improve the results of acquired physician practices through improved managed care contracting, improved collections, identification of growth initiatives and operating and cost savings based upon the significant infrastructure that we have developed.

Shared Services and Operational Initiatives

We have developed a number of strategic initiatives across our organization, in both our shared services functions and our operational infrastructure, with a goal of generating improvements in our general and administrative expenses and our operational infrastructure. In our shared services departments, we are focused on improving processes, using our resources more efficiently and utilizing our scale more effectively to improve cost and service performance across our operations. Within our operational infrastructure, we have developed specific operational plans within each of our service lines and affiliated physician practices, with specific milestones and regular reporting, with the goal of generating long-term operational improvements and fostering even greater collaboration across our national medical group. We currently intend to make a series of information-technology and other investments to improve processes and performance across our enterprise, using both internal and external resources. We are targeting annualized financial improvements related to these initiatives of $40 million within general and administrative expenses and $80 million in operational improvements by the end of 2019. We achieved the goals we established for these initiatives of $60 million in improvements in 2018, comprised of $25 million within shared services and $35 million in operational improvements, and we remain committed to achieve the remaining improvements by the end of 2019, although there is no assurance that these improvements will be obtained. We believe these strategic initiatives, together with our continued plans to invest in focused, targeted and strategic organic and acquisitive growth, position us well to deliver a differentiated value proposition to our stakeholders while continuing to provide the highest quality care for our patients.

Senior Notes

In February 2019, we completed a private offering of $500.0 million aggregate principal amount of 6.25% senior unsecured notes due 2027 (the “Additional 2027 Notes”), which are treated as a single class together with the 6.25% senior unsecured notes due 2027 that we issued in November 2018 (“the Initial 2027 Notes”), collectively (the “2027 Notes”). Our obligations under the 2027 Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee our credit agreement (the “Credit Agreement”). We used the net proceeds of approximately $491.7 million from the issuance of the Additional 2027 Notes to repay a portion of the indebtedness outstanding under our Credit Agreement. Interest on the 2027 Notes accrues at the rate of 6.25% per annum and is payable semi-annually in arrears on January 15 and July 15.

Common Stock Repurchase Programs

In July 2013, our Board of Directors authorized the repurchase of shares of our common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under our equity compensation programs. The share repurchase program allows us to make open market purchases from time-to-time based on general economic and market conditions and trading restrictions. The repurchase program also allows for the repurchase of shares of our common stock to offset the dilutive impact from the issuance of shares, if any, related to our acquisition program. We did not repurchase any shares under this program during the six months ended June 30, 2019.

In August 2018, we announced that our Board of Directors had authorized the repurchase of up to $500.0 million of shares of our common stock in addition to our existing share repurchase program, of which $250.0 million remained available as of December 31, 2018. Under this share repurchase program, during the six months ended June 30, 2019, we repurchased approximately 5.0 million shares of our common stock for $144.5 million, inclusive of 63,666 shares withheld to satisfy minimum statutory withholding obligations of $1.7 million in connection with the vesting of restricted stock.

We may utilize various methods to effect any future share repurchases, including, among others, open market purchases and accelerated share repurchase programs.

General Economic Conditions and Other Factors

Our operations and performance depend significantly on economic conditions. During the three months ended June 30, 2019, the percentage of our patient service revenue being reimbursed under government-sponsored or funded healthcare programs (the “GHC Programs”), was slightly favorable as compared to the three months ended June 30, 2018. If, however, economic conditions in the United States deteriorate, we could experience shifts toward GHC Programs, and patient volumes could decline. Further, we could experience and have experienced shifts toward GHC Programs if changes occur in population demographics within geographic locations in which we provide services. We have also experienced, and could continue to experience, a shift toward GHC Programs, particularly in anesthesia care. Payments received from GHC Programs are substantially less for equivalent services than payments received from commercial insurance payors. In addition, due to the rising costs of managed care premiums and patient responsibility amounts, we may experience lower net revenue resulting from increased bad debt due to patients’ inability to pay for certain services.

Healthcare Reform

The Patient Protection and Affordable Care Act (the “ACA”) contains a number of provisions that have affected us and, absent amendment or repeal, may continue to affect us over the next several years. These provisions include the establishment of health insurance exchanges to facilitate the purchase of qualified health plans, expanded Medicaid eligibility, subsidized insurance premiums and additional requirements and incentives for businesses to provide healthcare benefits. Other provisions have expanded the scope and reach of the Federal Civil False Claims Act and other healthcare fraud and abuse laws. Moreover, we could be affected by potential changes to various aspects of the ACA, including subsidies, healthcare insurance marketplaces and Medicaid expansion.

The ACA remains subject to continuing legislative and administrative flux and uncertainty. In 2017, Congress unsuccessfully sought to replace substantial parts of the ACA with different mechanisms for facilitating insurance coverage in the commercial and Medicaid markets. Additionally, Centers for Medicare & Medicaid Services (“CMS”) has administratively revised a number of provisions and may seek to advance additional significant changes through regulation, guidance and enforcement in the future. At the end of 2017, Congress repealed part of the ACA that required most individuals to purchase and maintain health insurance or face a tax penalty. The 2018 mid-term elections in November 2018 changed the balance of power in Congress and the results of the upcoming 2020 elections may change the direction of future health-related legislation. Several candidates for President have proposed legislation which would substantially modify the delivery of healthcare in the United States, including repealing the ACA and replacing all private insurance coverage with a government-sponsored plan such as Medicare.

If the ACA is repealed or further substantially modified, or if implementation of certain aspects of the ACA are diluted, delayed or replaced with a “Medicare for All” or single payor system, such repeal, modification or delay may impact our business, financial condition, results of operations, cash flows and the trading price of our securities. We are unable to predict the impact of any repeal, modification or delay in the implementation of the ACA, including the repeal of the individual mandate or implementation of a single payor system, on us at this time.

In addition to the potential impacts to the ACA under the current Administration and Congress, there could be more sweeping changes to GHC Programs, such as a change in the structure of Medicaid by converting it into a block grant or instituting “per capita caps,” which could eliminate the guarantee that everyone who is eligible and applies for benefits would receive them and could potentially give states sweeping new authority to restrict eligibility, cut benefits and make it more difficult for people to enroll. Additionally, several states are considering and pursuing changes to their Medicaid programs, such as requiring recipients to engage in employment activities as a condition of eligibility for most adults, disenrolling recipients for failure to pay a premium, or adjusting premium amounts based on income.

As a result, we cannot predict with any assurance the ultimate effect of these laws and resulting changes to payments under GHC Programs, nor can we provide any assurance that they will not have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities. Further, any fiscal tightening impacting GHC Programs or changes to the structure of any GHC Programs could have a material adverse effect on our financial condition, results of operations, cash flows and the trading price of our securities.

The Medicare Access and CHIP Reauthorization Act

Medicare pays for most physician services based upon a national service-specific fee schedule. The Medicare Access and CHIP Reauthorization Act (“MACRA”) provides physicians 0.5% annual increases in reimbursement through 2019 as Medicare transitions to a payment system designed to reward physicians for the quality of care provided, rather than the quantity of procedures performed. MACRA requires physicians to choose to participate in one of two payment formulas, Merit-Based Incentive Payment System (“MIPS”) or Alternative Payment Models (“APMs”). Effective January 1, 2019, MIPS allows eligible physicians to receive incentive payments based on the achievement of certain quality and cost metrics, among other measures, and be reduced for those who are underperforming against those same metrics and measures. As an alternative, physicians can choose to participate in advanced APMs, and physicians who are meaningful participants in APMs will receive bonus payments from Medicare pursuant to the law. MACRA also remains subject to review and potential modification by Congress, as well as shifting regulatory requirements established by CMS. We currently anticipate that our affiliated physicians will be eligible to receive bonus payments in 2019 through participation in the MIPS, although the amounts of such bonus payments are not expected to be material. We will continue to operationalize the provisions of MACRA and assess any further changes to the law or additional regulations enacted pursuant to the law.

We cannot predict the ultimate effect that these changes will have on us, nor can we provide any assurance that its provisions will not have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities.

Medicaid Expansion

The ACA also allows states to expand their Medicaid programs through federal payments that fund most of the cost of increasing the Medicaid eligibility income limit from a state’s historic eligibility levels to 133% of the federal poverty level. To date, 36 states and the District of Columbia have expanded Medicaid eligibility to cover this additional low-income patient population, and other states are considering expansion. All the states in which we operate, however, already cover children in the first year of life and pregnant women if their household income is at or below 133% of the federal poverty level.

“Surprise” Billing Legislation

“Surprise” medical bills arise when an insured patient receives care from an out-of-network provider resulting in costs that were not expected by the patient. The bill is a “surprise” either because the patient did not expect to receive care from an out-of-network provider, or because their cost-sharing responsibility is higher than the patient expected. For the past several years, state legislatures have been enacting laws that are intended to address the problems associated with surprise billing or balance billing.

More recently, Congress and President Trump have proposed bipartisan solutions to address this circumstance, either by working in tandem with, or in the absence of, applicable state laws. Any state or federal legislation on the topic of surprise billing may have an unfavorable impact on out-of network reimbursement that we receive. In addition, legislative changes in this area may impact our ability to contract with private payors at favorable reimbursement rates or remain in contract with such payors.

Although our out-of-network revenue is currently immaterial, we cannot predict the ultimate effect that these changes will have on us, nor can we provide any assurance that future legislation or regulations will not have a material adverse effect on our business, financial condition, results of operations, cash flows and the trading price of our securities.

Medicare Sequestration

The Budget Control Act of 2011, as amended by the American Taxpayer Relief Act of 2012, required across-the-board cuts (“sequestrations”) to Medicare reimbursement rates. These annual reductions of 2%, on average, apply to mandatory and discretionary spending through 2025. Unless Congress acts in the future to modify these sequestrations, Medicare reimbursements will be reduced by 2%, on average, annually. However, this reduction in Medicare reimbursement rates is not expected to have a material adverse effect on our business, financial condition, results of operations, cash flows or the trading price of our securities.

Non-GAAP Measures

In our analysis of our results of operations, we use certain non-GAAP financial measures. Prior to January 1, 2019, we reported earnings before interest, taxes and depreciation and amortization (“EBITDA”). During 2019, we have incurred and anticipate we will continue to incur certain expenses related to transformational and restructuring related expenses that are expected to be project-based and periodic in nature. In addition, we have reported our management services as assets held for sale and discontinued operations beginning with the first quarter of 2019. Accordingly, beginning with the first quarter of 2019, we began reporting Adjusted EBITDA from continuing operations, defined as income from continuing operations before interest, taxes, depreciation and amortization, and transformational and restructuring related expenses. Adjusted earnings per common share (“Adjusted EPS”) from continuing operations has also been further adjusted for these items and beginning with the first quarter of 2019 consists of diluted income from continuing operations per common and common equivalent share adjusted for amortization expense, stock-based compensation expense and transformational and restructuring related expenses. Adjusted EPS from continuing operations is being further adjusted to reflect the impacts from discrete tax events. Historical periods do not include any material items that meet the definition of transformational and restructuring related expenses, so although we are retrospectively presenting historical periods for the new definitions, we do not expect any adjustments for these items.

We believe these measures, in addition to income from operations, net income and diluted net income per common and common equivalent share, provide investors with useful supplemental information to compare and understand our underlying business trends and performance across reporting periods on a consistent basis. These measures should be considered a supplement to, and not a substitute for, financial performance measures determined in accordance with GAAP. In addition, since these non-GAAP measures are not determined in accordance with GAAP, they are susceptible to varying calculations and may not be comparable to other similarly titled measures of other companies.

For a reconciliation of each of Adjusted EBITDA from continuing operations and Adjusted EPS from continuing operations to the most directly comparable GAAP measures for the three and six months ended June 30, 2019 and 2018, refer to the tables below (in thousands, except per share data).

Three Months Ended June 30, 2019 2018 Six Months Ended June 30, 2019 2018
Income from continuing operations $35,516 $74,775 $77,169 $134,781
Interest expense 31,080 21,618 61,803 41,553
Income tax provision 17,116 28,482 26,078 51,202
Depreciation and amortization 19,809 20,280 39,842 40,195
Transformational and restructuring related expenses 27,482 — 31,026 —
Adjusted EBITDA from continuing operations $131,003 $145,155 $235,918 $267,731
Three Months Ended June 30, 2019 2018
Weighted average diluted shares outstanding 83,689 93,529
Income from continuing operations and diluted income from continuing operations per share $35,516 $0.42 $74,775 $0.80
Adjustments(1):
Amortization (net of tax of $3,434 and $3,621) 9,052 0.11 9,546 0.10
Stock-based compensation (net of tax of $2,739 and $2,840) 7,222 0.09 7,487 0.08
Transformational and restructuring related expenses (net of tax of $7,558) 19,924 0.24 — —
Net impact from discrete tax events 2,400 0.03 — —
Adjusted income and diluted EPS from continuing operations $74,114 $0.89 $91,808 $0.98

(1) Tax rate of 27.5% was used to calculate the tax effects of the adjustments for the three months ended June 30, 2019 and 2018, respectively. The tax rate used for the three months ended June 30, 2019 excludes the impact of discrete tax events.

Six Months Ended June 30, 2019 2018
Weighted average diluted shares outstanding 85,087 93,516
Income from continuing operations and diluted income from continuing operations per share $77,169 $0.91 $134,781 $1.44
Adjustments(1):
Amortization (net of tax of $6,883 and $7,183) 18,376 0.22 18,938 0.20
Stock-based compensation (net of tax of $5,709 and $5,503) 15,241 0.18 14,509 0.16
Transformational and restructuring related expenses (net of tax of $8,455) 22,571 0.26 — —
Net impact from discrete tax events (2,391) (0.03) — —
Adjusted income and diluted EPS from continuing operations $130,966 $1.54 $168,228 $1.80

(1) Tax rates of 27.3% and 27.5% were used to calculate the tax effects of the adjustments for the six months ended June 30, 2019 and 2018, respectively. The tax rate used for the six months ended June 30, 2019 excludes the impact of discrete tax events.

Results of Operations

Three Months Ended June 30, 2019 as Compared to Three Months Ended June 30, 2018

Our net revenue attributable to continuing operations was $868.3 million for the three months ended June 30, 2019, as compared to $865.0 million for the same period in 2018. The increase in revenue of $3.3 million, or 0.4%, was attributable to an increase in same-unit net revenue and revenue from acquisitions, partially offset by a decline in revenue from the non-renewal of certain contracts. Same units are those units at which we provided services for the entire current period and the entire comparable period. Same-unit net revenue grew by $13.0 million, or 1.6%. The increase in same-unit net revenue was comprised of a net increase of $8.9 million, or 1.1%, from patient service volumes and a net increase of $4.1 million, or 0.5%, related to net reimbursement-related factors. The increase in revenue from patient service volumes was related to increases across almost all of our service lines. The net increase in revenue related to net reimbursement-related factors was primarily due to modest improvements in managed care contracting.

Practice salaries and benefits attributable to continuing operations increased $16.0 million, or 2.7%, to $609.0 million for the three months ended June 30, 2019, as compared to $593.0 million for the same period in 2018. This increase was primarily attributable to increased costs associated with physicians and other staff to support organic-growth initiatives, acquisition-related growth and growth at our existing units, of which $7.8 million was related to salaries and $8.2 million was related to benefits and incentive compensation. We anticipate that we will continue to experience a higher rate of growth in clinician compensation expense at our existing units over historic averages, which could adversely affect our business, financial condition, results of operations, cash flows and the trading price of our securities.

Practice supplies and other operating expenses attributable to continuing operations decreased $0.3 million, or 1.1%, to $28.0 million for the three months ended June 30, 2019, as compared to $28.3 million for the same period in 2018. The decrease was primarily attributable to decreases in practice supply, rent and other costs.

General and administrative expenses attributable to continuing operations primarily include all billing and collection functions and all other salaries, benefits, supplies and operating expenses not specifically related to the day-to-day operations of our physician practices and services. General and administrative expenses were $103.5 million for the three months ended June 30, 2019, as compared to $100.9 million for the same period in 2018. General and administrative expenses for the three months ended June 30, 2019 included $3.5 million in cost improvements as part of our shared services initiative. General and administrative expenses as a percentage of net revenue was 11.9% for the three months ended June 30, 2019, as compared to 11.7% for the same period in 2018.

Transformational and restructuring related expenses attributable to continuing operations were $27.5 million for the three months ended June 30, 2019, of which $15.4 million related to severance benefits for eliminated positions as well as costs associated with contract terminations and $12.1 million related to external consulting costs for various process improvement and restructuring initiatives.

Depreciation and amortization expense attributable to continuing operations was $19.8 million for the three months ended June 30, 2019, as compared to $20.3 million for the same period in 2018.

Income from operations attributable to continuing operations decreased $41.9 million, or 34.2%, to $80.5 million for the three months ended June 30, 2019, as compared to $122.4 million for the same period in 2018. Our operating margin was 9.3% for the three months ended June 30, 2019, as compared to 14.1% for the same period in 2018. The decrease of 488 basis points was primarily due to higher operating expense growth combined with lower revenue growth.

Net non-operating expenses attributable to continuing operations were $27.9 million for the three months ended June 30, 2019, as compared to $19.1 million for the same period in 2018. The net increase of $8.8 million, or 46.1%, was primarily related to an increase in interest expense related to a higher average interest rate on our outstanding debt, driven by the incremental senior notes issuances completed in late 2018 and early 2019.

Our effective income tax rate attributable to continuing operations was 32.5% and 27.6% for the three months ended June 30, 2019 and 2018, respectively.

Income from continuing operations was $35.5 million for the three months ended June 30, 2019, as compared to $74.8 million for the same period in 2018. Adjusted EBITDA from continuing operations was $131.0 million for the three months ended June 30, 2019, as compared to $145.2 million for the same period in 2018.

Diluted income from continuing operations per common and common equivalent share was $0.42 on weighted average shares outstanding of 83.7 million for the three months ended June 30, 2019, as compared to $0.80 on weighted average shares outstanding of 93.5 million for the same period in 2018. Adjusted EPS from continuing operations was $0.89 for the three months ended June 30, 2019, as compared to $0.98 for the same period in 2018. The decrease of 9.8 million in our weighted average shares outstanding is primarily due to the impact of shares repurchased under a 2018 accelerated share repurchase program and through open market repurchase activity in 2018 and 2019.

Loss from discontinued operations was $43.8 million for the three months ended June 30, 2019, reflecting an incremental non-cash impairment charge recorded during the three months ended June 30, 2019, as compared to income from discontinued operations of $4.6 million for the same period in 2018. Diluted loss from discontinued operations per common and common equivalent share was $0.52 on weighted average shares outstanding of 83.7 million for the three months ended June 30, 2019, as compared to $0.05 on weighted average shares outstanding of 93.5 million for the same period in 2018.

Consolidated net loss was $8.2 million for the three months ended June 30, 2019, as compared to net income of $79.4 million for the same period in 2018. Diluted net loss per common and common equivalent share was $0.10 on weighted average shares outstanding of 83.7 million for the three months ended June 30, 2019, as compared to diluted net income per common and common equivalent share of $0.85 on weighted average shares outstanding of 93.5 million for the same period in 2018.

Six Months Ended June 30, 2019 as Compared to Six Months Ended June 30, 2018

Our net revenue attributable to continuing operations was $1.72 billion for the six months ended June 30, 2019 and 2018, reflecting a slight increase in revenue of $1.9 million, or 0.1%. The increase in revenue was attributable to an increase in same-unit net revenue, partially offset by a decline in revenue from the non-renewal of certain contracts and acquisitions. Same units are those units at which we provided services for the entire current period and the entire comparable period. Same-unit net revenue grew by $20.5 million, or 1.2%. The increase in same-unit net revenue was comprised of a net increase of $12.6 million, or 0.7%, from net reimbursement-related factors and a net increase of $7.9 million, or 0.5%, related to patient service volumes. The net increase in revenue related to net reimbursement-related factors was primarily due to modest improvements in managed care contracting and favorable rate impacts from our radiology services. The increase in revenue from patient service volumes was primarily related to growth in our neonatology and other pediatric services, partially offset by a decline in our anesthesiology services.

Practice salaries and benefits attributable to continuing operations increased $33.5 million, or 2.8%, to $1.23 billion for the six months ended June 30, 2019, as compared to $1.20 billion for the same period in 2018. This increase was primarily attributable to increased costs associated with physicians and other staff to support organic-growth initiatives, acquisition-related growth and growth at our existing units, of which $14.7 million was related to salaries and $18.8 million was related to benefits and incentive compensation. We anticipate that we will continue to experience a higher rate of growth in clinician compensation expense at our existing units over historic averages, which could adversely affect our business, financial condition, results of operations, cash flows and the trading price of our securities.

Practice supplies and other operating expenses attributable to continuing operations decreased $1.9 million, or 3.5%, to $53.8 million for the six months ended June 30, 2019, as compared to $55.7 million for the same period in 2018. The decrease was primarily attributable to decreases in practice supply, rent and other costs.

General and administrative expenses attributable to continuing operations primarily include all billing and collection functions and all other salaries, benefits, supplies and operating expenses not specifically related to the day-to-day operations of our physician practices and services. General and administrative expenses were $205.4 million for the six months ended June 30, 2019, as compared to $202.6 million for the same period in 2018. General and administrative expenses for the six months ended June 30, 2019 included $6.0 million in cost improvements as part of our shared services initiative. General and administrative expenses as a percentage of net revenue was 11.9% for the six months ended June 30, 2019, as compared to 11.8% for the same period in 2018.

Transformational and restructuring related expenses attributable to continuing operations were $31.0 million for the six months ended June 30, 2019 of which $16.3 million related to severance benefits for eliminated positions as well as costs associated with contract terminations and $14.7 million related to external consulting costs for various process improvement and restructuring initiatives.

Depreciation and amortization expense attributable to continuing operations was $39.8 million for the six months ended June 30, 2019, as compared to $40.2 million for the same period in 2018.

Income from operations attributable to continuing operations decreased $63.1 million, or 28.4%, to $159.0 million for the six months ended June 30, 2019, as compared to $222.1 million for the same period in 2018. Our operating margin was 9.2% for the six months ended June 30, 2019, as compared to 12.9% for the same period in 2018. The decrease of 369 basis points was primarily due to higher operating expense growth combined with lower revenue growth.

Net non-operating expenses attributable to continuing operations were $55.7 million for the six months ended June 30, 2019, as compared to $36.1 million for the same period in 2018. The net increase of $19.6 million, or 54.3%, was primarily related to an increase in interest expense related to a higher average interest rate on our outstanding debt, driven by the incremental senior notes issuances completed in late 2018 and early 2019 and the write off of approximately $1.5 million in deferred debt costs from the amendment of our Credit Agreement during the three months ended March 31, 2019.

Our effective income tax rate attributable to continuing operations was 25.3% and 27.5% for the six months ended June 30, 2019 and 2018, respectively.

Income from continuing operations was $77.2 million for the six months ended June 30, 2019, as compared to $134.8 million for the same period in 2018. Adjusted EBITDA from continuing operations was $235.9 million for the six months ended June 30, 2019, as compared to $267.7 million for the same period in 2018.

Diluted income from continuing operations per common and common equivalent share was $0.91 on weighted average shares outstanding of 85.1 million for the six months ended June 30, 2019, as compared to $1.44 weighted average shares outstanding of 93.5 million for the same period in 2018. Adjusted EPS from continuing operations was $1.54 for the six months ended June 30, 2019, as compared to $1.80 for the same period in 2018. The decrease of 8.4 million in our weighted average shares outstanding is primarily due to the impact of shares repurchased under a 2018 accelerated share repurchase program and through open market repurchase activity in 2018 and 2019.

Loss from discontinued operations was $328.3 million for the six months ended June 30, 2019, reflecting the loss on the initial classification as assets held for sale and an incremental impairment charge recorded during the six months ended June 30, 2019, as compared to income from discontinued operations of $8.1 million for the same period in 2018. Diluted loss from discontinued operations per common and common equivalent share was $3.86 on weighted average shares outstanding of 85.1 million for the six months ended June 30, 2019, as compared to diluted income from discontinued operations per common and common equivalent share of $0.09 on weighted average shares outstanding of 93.5 million for the same period in 2018.

Net loss was $251.1 million for the six months ended June 30, 2019, as compared to net income of $142.8 million for the same period in 2018. Diluted net loss per common and common equivalent share was $2.95 on weighted average shares outstanding of 85.1 million for the six months ended June 30, 2019, as compared to diluted net income per common and common equivalent share of $1.53 on weighted average shares outstanding of 93.5 million for the same period in 2018.

Liquidity and Capital Resources

As of June 30, 2019, we had $24.5 million of cash and cash equivalents attributable to our continuing operations as compared to $25.5 million at December 31, 2018. Additionally, we had working capital attributable to our continuing operations of $247.0 million at June 30, 2019, an increase of $118.0 million from working capital of $129.0 million at December 31, 2018. The net increase in working capital is primarily due to net borrowings on our Credit Agreement and reclassification of investments to available for sale, partially offset by the use of funds for repurchases of our common stock.

Cash Flows from Continuing Operations

Cash provided by (used in) operating, investing and financing activities from continuing operations is summarized as follows (in thousands):

Six Months Ended June 30, 2019 2018
Operating activities $54,922 $15,230
Investing activities (19,750) (30,996)
Financing activities (40,421) (4,761)

Operating Activities from Continuing Operations

During the six months ended June 30, 2019, our net cash provided by operating activities for continuing operations was $54.9 million, compared to $15.2 million for the same period in 2018. The net increase in cash provided of $39.7 million was primarily due to an increase in cash flow from accounts receivable, accounts payable and accrued expenses and income taxes payable, partially offset by a decrease in cash flow from lower earnings.

During the six months ended June 30, 2019, cash flow from accounts receivable for continuing operations was $2.5 million, as compared to cash used of $28.2 million for the same period in 2018. The increase in cash flow from accounts receivable for the six months ended June 30, 2019 was primarily due to decreases in ending accounts receivable balances at existing units due to timing of cash collections.

Days sales outstanding (“DSO”) is one of the key factors that we use to evaluate the condition of our accounts receivable and the related allowances for contractual adjustments and uncollectibles. DSO reflects the timeliness of cash collections on billed revenue and the level of reserves on outstanding accounts receivable. Our DSO for continuing operations was 52.8 days at June 30, 2019 as compared to 52.5 days at December 31, 2018.

Investing Activities from Continuing Operations

During the six months ended June 30, 2019, our net cash used in investing activities for continuing operations of $19.8 million included acquisition payments of $11.5 million and capital expenditures of $16.5 million, partially offset by proceeds of $8.2 million related to the maturity of investments.

Financing Activities from Continuing Operations

During the six months ended June 30, 2019, our net cash used in financing activities for continuing operations of $40.4 million consisted primarily of repurchases of $144.5 million of our common stock, partially offset by net borrowings on our Credit Agreement of $112.0 million.

Liquidity

On March 28, 2019, we amended and restated our Credit Agreement to reduce the size of the revolving credit facility, extend the maturity and make other technical and conforming changes. As amended and restated, the Credit Agreement provides for a $1.2 billion unsecured revolving credit facility and includes a $37.5 million sub-facility for the issuance of letters of credit. The Credit Agreement matures on March 28, 2024 and is guaranteed by substantially all of our subsidiaries and affiliated professional associations and corporations. At our option, borrowings under the Credit Agreement will bear interest at (i) the alternate base rate (defined as the higher of (a) the prime rate, (b) the Federal Funds Rate plus 1/2 of 1.00% and (c) LIBOR for an interest period of one month plus 1.00%) plus an applicable margin rate ranging from 0.125% to 0.750% based on our consolidated leverage ratio or (ii) the LIBOR rate plus an applicable margin rate ranging from 1.125% to 1.750% based on our consolidated leverage ratio. The Credit Agreement also calls for other customary fees and charges, including an unused commitment fee ranging from 0.150% to 0.200% of the unused lending commitments, based on our consolidated leverage ratio. The Credit Agreement contains customary covenants and restrictions, including covenants that require us to maintain a minimum interest charge ratio, not to exceed a specified consolidated leverage ratio and to comply with laws, and restrictions on the ability to pay dividends and make certain other distributions, as specified therein. Failure to comply with these covenants would constitute an event of default under the Credit Agreement, notwithstanding the ability of the company to meet its debt service obligations. The Credit Agreement also includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the Credit Agreement.

At June 30, 2019, we had an outstanding principal balance of $351.5 million on our Credit Agreement. We also had outstanding letters of credit of $0.2 million which reduced the amount available on our Credit Agreement to $848.3 million at June 30, 2019.

In February 2019, we completed a private offering of Additional 2027 Notes. At June 30, 2019, the outstanding balance on the 2027 Notes was $1.0 billion. We also had an outstanding principal balance of $750.0 million on our 5.25% senior unsecured notes due 2023 (the “2023 Notes”). Our obligations under the 2023 Notes and the 2027 Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee our Credit Agreement. Interest on the 2023 Notes accrues at the rate of 5.25% per annum, or $39.4 million, and is payable semi-annually in arrears on June 1 and December 1. Interest on the 2027 Notes accrues at the rate of 6.25% per annum, or $62.5 million, and is payable semi-annually in arrears on January 15 and July 15.

The indenture under which the 2023 Notes and the 2027 Notes are issued, among other things, limits our ability to (1) incur liens and (2) enter into sale and lease-back transactions, and also limits our ability to merge or dispose of all or substantially all of our assets, in all cases, subject to a number of customary exceptions. Although we are not required to make mandatory redemption or sinking fund payments with respect to the 2023 Notes and the 2027 Notes, upon the occurrence of a change in control of MEDNAX, we may be required to repurchase the 2023 Notes and the 2027 Notes at a purchase price equal to 101% of the aggregate principal amount of the 2023 Notes and the 2027 Notes repurchased plus accrued and unpaid interest.

At June 30, 2019, we believe we were in compliance, in all material respects, with the financial covenants and other restrictions applicable to us under the Credit Agreement and the 2023 Notes and the 2027 Notes. We believe we will be in compliance with these covenants throughout 2019.

We maintain professional liability insurance policies with third-party insurers, subject to self-insured retention, exclusions and other restrictions. We self-insure our liabilities to pay self-insured retention amounts under our professional liability insurance coverage through a wholly owned captive insurance subsidiary. We record liabilities for self-insured amounts and claims incurred but not reported based on an actuarial valuation using historical loss information, claim emergence patterns and various actuarial assumptions. Our total liability related to professional liability risks at June 30, 2019 was $260.0 million, of which $44.8 million is classified as a current liability within accounts payable and accrued expenses in the Consolidated Balance Sheet. In addition, there is a corresponding insurance receivable of $26.3 million recorded as a component of other assets for certain professional liability claims that are covered by insurance policies.

We anticipate that funds generated from operations, together with our current cash on hand and funds available under our Credit Agreement, will be sufficient to finance our working capital requirements, fund anticipated acquisitions and capital expenditures, fund expenses related to our transformational and restructuring activities, fund our share repurchase programs and meet our contractual obligations for at least the next 12 months from the date of issuance of this Form 10-Q.

Caution Concerning Forward-Looking Statements

Certain information included or incorporated by reference in this Quarterly Report may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions, and are based on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this Quarterly Report are made as of the date hereof, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the 2018 Form 10-K, including the section entitled “Risk Factors.”

Market risk

As filed, 678 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We are subject to market risk primarily from exposure to changes in interest rates based on our financing, investing and cash management activities. We intend to manage interest rate risk through the use of a combination of fixed rate and variable rate debt. We borrow under our Credit Agreement at various interest rate options based on the Alternate Base Rate or LIBOR rate depending on certain financial ratios. At June 30, 2019, the outstanding principal balance on our Credit Agreement was $351.5 million, and considering this outstanding balance, a 1% change in interest rates would result in an impact to income before income taxes of approximately $3.5 million per year.

Controls and procedures

As filed, 1,380 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed by the Company in reports it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and (ii) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2019.

Changes in Internal Controls Over Financial Reporting

No changes in our internal control over financial reporting occurred during the three months ended June 30, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2019-04-01 to 2019-06-30$868.3mus-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
Revenue6 months2019-01-01 to 2019-06-30$1.72bnus-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
Operating income3 months2019-04-01 to 2019-06-30$80.5mus-gaap:OperatingIncomeLoss
Operating income6 months2019-01-01 to 2019-06-30$159.0mus-gaap:OperatingIncomeLoss
Interest expense3 months2019-04-01 to 2019-06-30$31.1mus-gaap:InterestExpense
Interest expense6 months2019-01-01 to 2019-06-30$61.8mus-gaap:InterestExpense
Income tax3 months2019-04-01 to 2019-06-30$17.1mus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2019-01-01 to 2019-06-30$26.1mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2019-04-01 to 2019-06-30−$8.2mus-gaap:NetIncomeLoss
Net income6 months2019-01-01 to 2019-06-30−$251.1mus-gaap:NetIncomeLoss
Diluted EPS3 months2019-04-01 to 2019-06-30−$0.10us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2019-01-01 to 2019-06-30−$2.95us-gaap:EarningsPerShareDiluted
Basic EPS3 months2019-04-01 to 2019-06-30−$0.10us-gaap:EarningsPerShareBasic
Basic EPS6 months2019-01-01 to 2019-06-30−$2.97us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2019-04-01 to 2019-06-3083,689,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2019-01-01 to 2019-06-3085,087,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2019-01-01 to 2019-06-30$62.8mus-gaap:NetCashProvidedByUsedInOperatingActivities
Share repurchases6 months2019-01-01 to 2019-06-30$144.5mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2019-06-30$24.5mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2019-06-30$985.5mus-gaap:AssetsCurrent
Total assetsAt period end2019-06-30$5.64bnus-gaap:Assets
Current liabilitiesAt period end2019-06-30$441.0mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2019-06-30$2.91bnus-gaap:Liabilities
Shareholders' equityAt period end2019-06-30$2.73bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001193125-19-210927. Last ingested by Listed: Oct 29, 2026, 07:14 ET. Listed shows no prices and gives no investment advice.